NASDAQ · FRES
Healthcare · Biotechnology
$0.85
Down-$0.26 (-23.42%)
Updated Aug 23, 2026, 6:41 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
FRES does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning FRES.
FRES research
Company profile and research snapshot.
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
proactiveinvestors.co.uk · Nov 10, 2025
Precious metals miners Fresnillo PLC (LSE:FRES), Endeavour Mining PLC (LSE:EDV, TSX:EDV, OTCQX:EDVMF) and Hochschild Mining PLC (LSE:HOC, OTCQX:HCHDF) were among the early FTSE 350 leaders on Monday as gold and silver prices rebounded strongly. The spot price of gold was up 1.9% to $4,078.2 an ounce, while silver was up 3% to $49.92 an ounce.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FRES.
No results
No recent SID articles mention FRES.
